Novo Nordisk's CFO expects US growth boost this year

In spite of price pressure in the insulin business and increased US competition Novo Nordisk's CFO expects the company to grow its US business in 2021.

Novo Nordisk CFO Karsten Munk Knudsen | Photo: Novo Nordisk / PR

Novo Nordisk expects to turn its US growth up a notch, since the company is back to growing on this market after a stagnation and price pressure-riddled 2019.

Novo's total US sales rose 3 percent in local currency to DKK 57.8bn (USD 9.3bn) last year, and it will be even better this year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs